ABEO Abeona Therapeutics
- 4.4700
- +0.0200+0.45%
Abeona Therapeutics News
Express News | Abeona Therapeutics Inc Files for Mixed Shelf of up to $300 Mln - SEC Filing
Express News | Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersMyMD Pharmaceuticals (NASDAQ:MYMD) stock rose 46.0% to $2.89 during Thursday's after-market session. The market value of their outstanding shares is at $6.6 million. Adaptimmune Therapeutics (N
Abeona Therapeutics Inc.: Stifel starts insurance with a purchase rating; target price is $21
Abeona Therapeutics Inc.: Stifel starts insurance with a purchase rating; target price is $21
Express News | Abeona Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Target Price $21
Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference
CLEVELAND, May 28, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced that members of its senior management team will participate in a fireside chat at the Jefferies Global Healthcare
Abeona Therapeutics(ABEO.US) Director Buys US$51,799 in Common Stock
$Abeona Therapeutics(ABEO.US)$ Director Alland Leila purchased 11,000 shares of common stock on May 16, 2024 at an average price of $4.709 for a total value of $51,799.Source: Announcement What is sta
Abeona Therapeutics Is Maintained at Overweight by Cantor Fitzgerald
Abeona Therapeutics Is Maintained at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Lowers Price Target to $21
Cantor Fitzgerald analyst Kristen Kluska maintains Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and lowers the price target from $28 to $21.
Abeona Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 360.53% Cantor Fitzgerald $28 → $21 Maintains Overweight 04/23/2024 689.47% Cantor Fitzgerald →
Abeona Therapeutics Inc (ABEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...
Q1 2024 Abeona Therapeutics Inc Earnings Call
Abeona Therapeutics Shares Are Trading Higher. The Company Reported Q1 Financial Results.
Abeona Therapeutics Shares Are Trading Higher. The Company Reported Q1 Financial Results.
ABEONA THERAPEUTICS INC. Q1 Loss Increases, Misses Estimates
Abeona Therapeutics Estimates That Its Current Cash And Cash Equivalents, Restricted Cash And Short-term Investments Of $62.7M, Credit Facility, And Proceeds Of $75M From Underwritten Offering In May Is Expected To Provide Cash Runway Into 2026
Abeona Therapeutics Estimates That Its Current Cash And Cash Equivalents, Restricted Cash And Short-term Investments Of $62.7M, Credit Facility, And Proceeds Of $75M From Underwritten Offering In May
Abeona Therapeutics Q1 2024 GAAP EPS $(1.16) Misses $(0.51) Estimate
Abeona Therapeutics Q1 2024 GAAP EPS $(1.16) Misses $(0.51) Estimate
Abeona Therapeutics | 10-Q: Quarterly report
Abeona Therapeutics 1Q Loss/Shr $1.16 >ABEO
Abeona Therapeutics 1Q Loss/Shr $1.16 >ABEO
Press Release: Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress BLA resubmission anticipated in second half of 2024 Closed $75 million underwritten offering in May, ex
Plunge for Elodie Raises $2.5M+ for Life-Saving Rare Disease Research in Just 7 Years
Celebrities, sports teams, schools and supporters across 20+ locations worldwide take polar plunges to raise awareness and funds for rare genetic skin disorder called EBNEW YORK, May 7, 2024 /PRNewsw
Analysis
Price Target
No Data
